SAR 260301

Drug Profile

SAR 260301

Alternative Names: SAR260301

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 04 Oct 2017 Sanofi completes a phase I trial for Lymphoma, Solid tumours and Malignant melanoma (Late-stage disease) in USA and Canada (PO) (NCT01673737)
  • 05 Feb 2015 Discontinued - Phase-I for Malignant melanoma (Late-stage disease) in Canada (PO)
  • 05 Feb 2015 Discontinued - Phase-I for Lymphoma (Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top